Promoter holding
64.27%
BP
Bacil Pharma Ltd - Due diligence report
A 360° intelligence report on Bacil Pharma Ltd: trust score, financial health, credit view, compliance, directors, growth and distress signa…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Bacil Pharma Ltd — 360° Intelligence Report
Generated from MCA filings & public records70/100
Trust Score
Moderate
Bacil Pharma Ltd is assessed as Moderate with a Trust Score of 70/100. Bacil Pharma Ltd is an active public limited indian non-government company incorporated in 1987, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.
Report generated on 11 Oct 2026 from the latest processed filings. Bacil Pharma Ltd snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
70/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
51/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
60/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
75/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 60/100 Moderate
- Negative operating earnings - debt service depends on external support.
- No open charges - unencumbered balance sheet.
- Moderate gearing (D/E 38%).
- Working-capital cover adequate.
Charges position: 0 open (-) · 0 satisfied (-).
Compliance Score: 51/100 Moderate
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2025).
- Flagged by authority: BSE.
- Litigation present in 1 court forum(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 75/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| TAK BHAVANA TAK | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DIKSHANT SINGH PANWAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Jayesh Ramchandra Patil | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Mehul Hasmukhbhai Shah | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Omprakash Pyarelal Sonar | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Chaitali Kalpataru Shah | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Chaitali Kalpataru Shah | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Vivek Mukesh Yadav | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 8 directors on the board.
- No disqualified or deactivated DINs.
- 8 director exits in 3 years - high churn.
Director & KMP remuneration (FY 2021)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2021 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
0 allotment(s) · 7 transfer(s)
Promoters hold the largest single block of equity - exact percentages are part of the full report.
Key managerial personnel: Jayesh Ramchandra Patil (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 70 · Distress 80
Growth signals & trust indicators
Steady revenue growth: +1.42 over 4 year(s).
Latest year revenue grew 2.1x.
Operating for 39+ years.
Distress signals & risk flags
3 director exits within 2 years.
Compliance score is weak (51/100).
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence65/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment61/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance gaps should be priced into terms.
Investor view70/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Jun 2026
Director appointed
Omprakash Pyarelal Sonar (Additional Director)
Director appointed
Vivek Mukesh Yadav (Additional Director)
19 Dec 2025
Director appointed
DIKSHANT SINGH PANWAR (Company Secretary)
29 Sep 2025
Last AGM held
Annual general meeting
12 Aug 2025
Director appointed
Chaitali Kalpataru Shah (Cfo)
Director ceased
GANPAT DHONDU SALEKAR
22 Jul 2025
Director ceased
PRAKASH BHOORCHAND SHAH
16 Jul 2025
Director appointed
Chaitali Kalpataru Shah (Additional Director)
10 Jul 2025
Director ceased
JAYESH RAMCHANDRA PATIL
31 Mar 2025
Latest balance sheet
Filed with ROC
27 Sep 2024
Director ceased
SHIRISH SURYAKANT SHETYE
Director ceased
LALIT JAIN
26 Sep 2024
Director ceased
DINESH CHANDER NOTIYAL
Director ceased
AVANI SAVJIBHAI GODHANIYA
31 Aug 2024
Director appointed
Mehul Hasmukhbhai Shah (Director)
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Debt-to-equity stands at 0.86 - manageable leverage.
Net worth is positive.
8 active director(s) / partner(s); board looks stable and experienced.
Promoters hold the largest single block of equity as per the FY 2021 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
| Company | CIN | Location |
|---|---|---|
| Bigcarat Bullion Private Limited | U51909MH2021PTC367369 | Mumbai, Maharashtra |
| Saivmor Power Private Limited | U31909MH2008PTC181434 | Raigarh, Maharashtra |
| Goldcom Consultancy Services P Ltd | U74140MH1993PTC075004 | Mumbai, Maharashtra |
| Telesource Executive Search India Private Limited | U74910MH2003PTC139110 | Raigarh, Maharashtra |
| Taj Gcc Air Caterers Pvt Ltd | U55204MH1993PTC072626 | Raigarh, Maharashtra |
| Devaunshi Investments Private Limited | U67120MH1976PTC018933 | Mumbai, Maharashtra |
| Kwok Marine Services Private Limited | U63090MH2000PTC125668 | Raigarh, Maharashtra |
| YOGINI MERCANTILE LLP | AAH-6937 | Raigarh(mh), Maharashtra |
| Ketchum Sampark Private Limited | U74140MH1996PTC102090 | Mumbai, Maharashtra |
| C N Sanghavi And Company (Forwards) Private Limited | U63090MH2003PTC140424 | Mumbai, Maharashtra |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Bacil Pharma Ltd before audits and certifications: compliance score 51/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Bacil Pharma Ltd: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 60/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 70/100, margin trends, ownership structure and peer set for Bacil Pharma Ltd - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 70/100, distress signals and MSME payment-delay disclosures - know whether Bacil Pharma Ltd pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Bacil Pharma Ltd - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Bacil Pharma Ltd an active company?
Bacil Pharma Ltd has MCA status “Active” with a compliance score of 51/100 (Moderate).
Is Bacil Pharma Ltd financially healthy?
Bacil Pharma Ltd has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.
Should I do business with Bacil Pharma Ltd?
Its overall Trust Score is 70/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Bacil Pharma Ltd?
Promoters hold the largest single block of equity - exact percentages are in the full report. 8 active director(s) are on record.
Does Bacil Pharma Ltd have loans or charges against its assets?
No charges are registered against this company - an unencumbered balance sheet.
Is Bacil Pharma Ltd up to date with its ROC filings?
Balance sheet slightly behind (Mar 2025). Overall compliance score: 51/100 (Moderate).
Is it risky to lend to Bacil Pharma Ltd?
Its Credit Risk Score is 60/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
